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Abstract
Background
Retracing and biomarker characterization of individual
circulating tumour cells (CTCs) may potentially contribute
to personalized metastatic cancer therapy. This is relevant
when a biopsy of the metastasis is complicated or impos‐
sible to acquire.
Methods
A novel disc format was used to map and retrace individual
CTCs from breast-cancer patients and nucleated cells from
healthy blood donors using the CytoTrack platform. For
proof of the retracing concept, CTC HER2 characterization
by immunofluorescence was tested.
Results
CTCs were detected and enumerated in three of four blood
samples from breast-cancer patients and the locations of
each individual CTCs were mapped on the discs. Nucleat‐
ed cells were retraced on seven discs with 96.6%±8.5%
recovery on five fields of view on each disc. Shifting of field
of view for retracing was measured to 4-29 µm. In a blood
sample from a HER2-positive breast-cancer patient, CTC
enumeration and mapping was followed by HER2 charac‐
terization and retracing to demonstrate downstream
immunofluorescence analysis of the CTC.
Conclusion
Mapping and retracing of CTCs enables downstream
analysis of individual CTCs for existing and future cancer
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genotypic and phenotypic biomarkers. Future studies will
uncover this potential of the novel retracing technology.
Keywords CytoDisc, Ciculating tumor cells, CytoTrack,
Cancer, HER2, CTC, Characterization, Enumeration, Breast
cancer, Immunofluorescence, CK, Liquid biopsy, Method,
Retracing, Metastasis
1. Introduction
One of the hallmarks of cancer is tumour heterogeneity and
genomic instability, which is a particular challenge in
adjuvant treatment strategies [1,2]. Several biomarker-
based tests for characterization of tumour tissue are used
in clinical practice for directing treatments, and their
number is rapidly increasing [3]. Today, these tests are
predominantly performed on primary tumour tissue,
although patients with relapse ultimately suffer from the
direct sequelae of the metastatic lesions. Tumour-cell
migration demands a transformation process (epithelial-
mesenchymal transition), so phenotypical appearance may
change compared to the characteristics of the primary
tumour [4,5]. Furthermore, continuous genetic drift due to
various sources – and subsequent natural selection in
tumour cells over time and under treatment – results in
heterogeneity both within the primary tumour and in
descendant metastatic lesions. The clinical importance of
heterogeneity is evident both within primary tumours and
between primary tumours and metastases [6]. Thus, there
is a need for biochemical characterization of the metastatic
lesion for tailor-made therapy; however, the inaccessibility
of the metastatic sites is challenging, and taking a biopsy
can be a cumbersome procedure for the patient. Analysing
circulating tumour cells (CTCs) as a surrogate for the
metastatic lesion may improve treatment decisions and
patient outcomes [7,8].
For more than a century it has been known that cancer cells
detach from tumours and circulate in the blood stream, but
only contemporary methods are capable of both detecting
and enumerating the rare cells in the blood [9,10]. CTCs can
repeatedly be isolated from peripheral blood of most cancer
patients. Methods used in clinical practice are limited to
enumeration of CTCs, where the number is predictive of
outcome and is therefore of limited benefit for patients [11].
A blood sample containing CTCs is often referred to as a
‘liquid biopsy’ and may provide proxies of metastatic
cancers [12,13]. The clinical significance of the intra- and
intermetastatic heterogeneity still needs to be established.
Like metastases, CTCs are probably heterogeneous popu‐
lations of cells; however, they are of limited number and
may not be able to reflect the heterogeneous nature of
human cancers.
However, methods for characterization of CTC biomarkers
are considered to have great promise for the practical
implementation of personalized cancer treatment [7,13].
This may involve evaluation of the detected CTCs with,
e.g., immunofluorescence or fluorescence in-situ hybridi‐
zation (FISH) – always requiring retracing of the CTCs.
CytoTrack™ is a novel scanning and imaging concept
bridging flow cytometry and fluorescence microscopy [10].
From peripheral blood, all nucleated blood cells including
CTCs are isolated and immobilized onto a round glass disc.
In this study, a novel disc format called CytoDisc™ was
assessed; alongside enumeration, the disc provides an
accurate location of each CTC for potential downstream
phenotypic or genotypic evaluation (Figure 1). The disc is
tested with regard to the accuracy of mapping and retracing
CTCs, and HER2 immunofluorescence is applied to test
downstream biomarker characterization potential.
2. Materials and Methods
2.1 Clinical specimens
From metastatic breast cancer patients, samples of 7.5 mL
peripheral blood were collected in CellSave Preservative
Tubes (Veridex, Raritan, NJ, USA). The tubes were shipped
and stored at ambient temperature and analysed within
four days. The patients were from The Maria Sklodowska-
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Figure 1. CytoDisc with ‘notch’ for repositioning. The area of the CytoDisc is 120 cm2, 
sufficient for a monolayer of more than 100 million nucleated blood cells. 
 
Figure 1. CytoDisc with ‘notch’ for repositioning. The area of the CytoDisc is 120 cm2, sufficient for a monolayer of more than 100 million nucleated blood
cells.
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Curie Memorial Cancer Centre and Institute of Oncology,
Warsaw, Poland, and written informed consent was
obtained from each participant prior to sample collection.
The study was approved by the Ethics Committee of the
Maria Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology (No13/2008).
The 707528 patient was diagnosed with ER-pos, PgR-pos
and HER2-neg (1+), Ki67>14% multifocal infiltrating ductal
carcinoma, stage IIA. She had a mastectomy in 2009 and in
2012 a recurrence of carcinoma at the site of surgery.
Reoperation was performed, followed by tamoxifen
treatment and radiotherapy. In 2013, bone metastases were
found, and the patient was treated with chemotherapy and
palliative radiotherapy. The patient is now treated with
denosumab.
The 1067856 patient was diagnosed in July 2014 with
infiltrating ductal carcinoma, ER-10%, PgR-100%, HER2-
neg (0), primary IIB stage with metastasis to bone, skin and
lymph nodes, Ki67-10%. In September 2014 she was treated
with letrozol and had bone radiotherapy. Now, the patient
is treated with denosumab.
The 1033919 patient was diagnosed in 2013 with infiltrating
ductal carcinoma, stage IIB, G3, ER-0%, PgR-0% and HER2-
pos (3+), Ki67- 80%. The patient was treated with trastuzu‐
mab followed by a mastectomy in August 2014. In
September 2014, metastasis to bone and liver, and recur‐
rence in chest wall were found. The patient is now treated
with lapatinib and capecitabine.
The 673451 patient was diagnosed in 2002 with invasive
ductal carcinoma G3, pT2N0, ER-50%, PgR-0%, HER2- neg.
A radical mastectomy in January 2003 was followed by
adjuvant chemotherapy. She has metastasis to lung, bone,
lymph node and soft tissue of the skull base. The patient
was treated with palliative chemotherapy with docetaxel
and cisplatin.
The 790864 patient was diagnosed with ER-neg, PgR-neg
and HER2-pos (2+), ductal carcinoma, cT3NxM0 in 2007.
Following four courses of AC chemotherapy she under‐
went a radical mastectomy, and, because of lymph-node
involvement, she was treated with adjuvant therapy and
trastuzumab. In 2014 metastasis to bone and bone marrow
was found, and the patient was treated with paxitaxel and
denosumab. In April 2015 liver progression was diagnosed,
and change of treatment is planned.
2.2 Donor Specimens
Peripheral blood samples from healthy donors (Nordsjæl‐
lands Hospital, Hillerød, Denmark) were collected in
EDTA-tubes and analysed within four hours. Written
informed consent was obtained from each donor.
2.3 CTC enumeration
CTCs were enumerated according to the manufacturer’s
instructions (Figure 2). Briefly, blood samples were
centrifuged at 2500 g for 15 minutes and the buffy-coat
layer with nucleated cells and possible CTCs were trans‐
ferred to 15 mL tubes. Remaining red blood cells were lysed
and nucleated cells were fixed with FACS Lysing solution
(BD Biosciences) for 15 minutes and centrifuged at 2500 g
for 15 minutes. CTCs were stained using CTC Stain
(CytoTrack ApS, Lyngby, Denmark) comprising a mixture
of anti-CD45/NIR antibody, anti-EpCAM/Yellow and anti-
cytokeratin/Green antibody and nuclear-stain DAPI for
one hour at 2-8°C in darkness. Subsequently, the cells were
washed with PBS with 1% BSA and re-suspended in 1 mL
H2O. The cell suspension was smeared onto the CytoDisc,
air-dried, mounted using mounting medium (Olink
Bioscience, Uppsala, Sweden), covered with a CytoCover™
(CytoTrack) and sealed with rubber cement (FixoGum,
Marabu Scandinavia, Denmark) along the edge. The
CytoDisc was inserted into a CytoTrack CT4 platform
(CytoTrack) and locked into position using the ‘notch’ on
the CytoDisc (Figure 1) and focused using the five pre-set
focus points. Subsequently, CTCs were detected and
enumerated by scanning using the Green channel with a
20x scanning objective. Scanning was performed within
one week of staining. Green events were recorded and
listed in a hotspot table. Recorded events were visually
inspected by the operator in the Green channel and an
image gallery was automatically generated using DAPI,
Green and NIR channels and 20x imaging objective from
positions on the CytoDisc with possible CTCs. The image
gallery was analysed using the following morphologic
criteria: nearly round and size >4 µm, with visible DAPI-
positive nucleus with at least 50% association with the
cytoplasm, cytokeratin-positive, and CD45-negative. The
definition of CTC is similar to the definition used by other
CTC analysis methods [14-18].
2.4 CTC Mapping
A map of positions of individual CTCs on the CytoDisc was
constructed after scanning the blood samples from breast-
cancer patients.
2.5 Retracing of cells on CytoDisc
The FixoGum seal was removed and the CytoDisc with
CytoCover was immersed in PBS in a 145-mm-diameter
Petri dish. After approximately 15 minutes the CytoDisc
was carefully lifted into a vertical position allowing the
CytoCover to gently slide off, and was carefully washed
with PBS to remove remaining mounting medium. The
CytoDisc was air dried and subsequently stored refriger‐
ated. The CytoDisc was then inserted into the CytoTrack
scanner and locked into position using the ‘notch’ (Figure
1). Five fields of view on the five focus points for the
CytoDisc were captured and the number of cells was
counted in each field of view using ImageJ before and after
removal of CytoCover and mounting medium. Cell
recovery was investigated by retracing cells in five fields of
view using ImageJ (version 1.48v), an open-source image-
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processing program for cell counting. The cell counts were
used for estimation of the recovery, i.e., all cells were
counted on selected fields of view on the CytoDisc and the
same fields of view were retrieved and counted again. First,
images were turned into greyscale and the threshold was
adjusted to highlight all the objects to be counted. To
eliminate noise, the background was subtracted with a
rolling ball with a radius of 50 pixels. The ‘Watershed’
function was applied in cases where objects were merged
together. The function ‘Analyse particles’ was used to
count objects. Only particles with pixel size above 300 and
circularity within the range of 0-1.0 were encountered. If
the cells had shifted position at the second count (recovery),
the shifted distance was measured using ImageJ.
The following variations to the manufacturer’s standard
procedure (see CTC enumeration under Materials and
Methods) were tested to see whether they had any effect on
retracing of the blood cells: 1. Drying the cell smear on the
CytoDisc at 37°C instead of room temperature. 2. For re-
suspension of the cell pellet, 0.5 mL and 2 mL H2O was used
instead of the standard 1 mL H2O. 3. During the cell-smear
drying process at room temperature, the CytoDisc was
continuously rotated automatically to test if this improved
the cell distribution for detection, enumeration and
retracing. 4. Storage of the CytoDisc for up to four weeks at
2-8°C was also studied. The CytoDisc was scanned and
rescanning/retracing was performed three and four weeks
later.
2.6 HER2 Characterization
After enumeration, one patient sample (ID790864) was
HER2-stained and the CTCs were retraced for characteri‐
zation. On the CytoDisc with the enumerated CTCs, 400 µl
of HER2/NIR antibody (clone 24D2, Biolegend, San Diego,
CA) diluted 1:200 in PBS were applied, and a CytoCover
was put on top to ensure uniform coverage of the disc
surface. The CytoDisc was incubated for 1 hr at room
temperature in a closed Petri dish. After incubation, the
CytoCover was removed and the CytoDisc washed with
PBS as described above. After air-drying, mounting
medium and CytoCover were applied.
3. Results
3.1 CTC enumeration and mapping
Enumeration of CTCs was conducted in four specimens
from four metastatic breast cancer patients. CTCs were
detected in three of the samples and enumerated at 189, one
and five, respectively. The presence of individual CTCs at
all map positions was confirmed by imaging. Representa‐
tive results of CTCs linking images of individual CTCs to
the map locations are shown in Figure 3 for each of the three
specimens.
3.2 Cell recovery and precision
The cell recovery of the retracing procedure using seven
blood-donor samples was analysed by the standard
procedure for CTC enumeration. For one sample, recovery
was measured three times over a one-month period. In
addition, variations to the standard procedure were also
investigated. The results are summarized in Table 1.
Overall recovery for the standard procedure was 97%.
None of the modifications to the standard procedure, i.e.,
higher and lower amount of H2O for pellet re-suspension,
heating to 37°C during drying, and rotating of the Cyto‐
Disc, showed an impact on cell recovery.
Images of one field of view for the CytoDisc where retrac‐
ing was performed three times are shown in Figure 4.
Shifting of field of view position is illustrated by the shift
of a red circle around one individual cell. The actual shifting
distance was 4, 29 and 24 µm, respectively, relatively small
compared to the size of the field of view of 510 x 384 µm.
Cell counting is illustrated in Figure 5 and shows that very
few cells are lost in the process and most of the differences
before and after retracing are due to counting errors for
clusters of cells and cells on the edges. The recovery may







Figure 2. The CytoTrack system is a scanning and imaging technology bridging flow cytometry and fluorescence microscopy. After detection and enumeration
of CTCs, each individual CTC can be further analysed for instance for immunofluorescence (e.g., HER2 antibody). By reinserting the CytoDisc in the CytoTrack
system, CTCs can be retraced and characterized by imaging.
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Figure 3. Representative examples of CTCs from three breast-cancer patients (ID 707528, 
1067856 and 673451) with 189, one and five CTCs, respectively. Images (anti-
cytokeratin/Green, nuclear stain DAPI/Blue, anti-CD45/NIR) confirm the presence of 
individual CTCs at the locations on the map. 
 
Figure 3. Representative examples of CTCs from three breast-cancer patients (ID 707528, 1067856 and 673451) with 189, one and five CTCs, respectively. Images
(anti-cytokeratin/Green, nuclear stain DAPI/Blue, anti-CD45/NIR) confirm the presence of individual CTCs at the locations on the map.
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Within* CytoDisc Total CytoDisc
Recovery CV% Recovery CV%
1 Standard1 Same day 97% 2.3%
96.6% 8.5%
2 Standard Same day 98% 4.5%
3 Standard Same day 98% 6.6%
4 Standard Same day 95% 10.3%
5 Standard Same day 93% 17.0%
6 Standard Same day 98% 10.7%
7 Standard Same day 97% 8.1%
7 Standard Same day 97% 8.1%
96.0% 13.8%7 Standard 3 weeks 96% 19.3%
7 Standard 4 weeks 96% 14.1%
8 Drying 37°C2 Same day 97% 2.3%
100% 4.6%8 Drying 37°C 3 weeks 104% 7.3%
8 Drying 37°C 4 weeks 99% 4.2%
9 0.5 mL H2O3 Same day 104% 10.3%
109% 10.3%9 0.5 mL H2O 3 weeks 111% 11.2%
9 0.5 mL H2O 4 weeks 111% 9.3%
10 2 ml H2O4 Same day 99% 3.6%
11 Rotating5 Same day 97% 7.0%
1CTC enumeration according to manufacturer’s instructions
2CTC enumeration according to 1, but modified by drying cell smear on CytoDisc at 37°C.
3 CTC enumeration according to 1, but modified by use of 0.5 mL H2O for cell pellet re-suspension.
4 CTC enumeration according to 1, but modified by use of 2 mL H2O for cell pellet re-suspension.
5 CTC enumeration according to 1, but modified by an automated continuous rotation of the disc during drying of cell smear at room temperature.
*Five preset focus points (fields of view) on the CytoDisc
Table 1. Recovery for retracing of nucleated cells
3.3 HER2 characterization of individual CTCs
A blood sample from a patient with HER2-positive primary
tumour (ID 790864) was used to exemplify the process of
CTC enumeration followed by HER2 characterization of
the individual CTCs. The same channel/dye fluorescence
was used for both CD45 (negative control for CTC enu‐
meration) and HER2 characterization. This way HER2
characterization could be observed as NIR staining of the
CTC after staining with HER2/NIR antibody. A total of four
CTCs were enumerated and the positions mapped. After
removal of CytoCover and mounting medium, HER2
characterization was performed and the individual CTCs
were all retraced and shown to be HER2-positive, as
illustrated in Figure 6.
4. Discussion
CTCs may serve as a liquid biopsy in metastatic cancer, and
this must involve CTC characterization beyond detection
and enumeration. Thus, CTCs need to be retraced for
further analysis. We found that retracing of blood cells on
the CytoDisc is possible after up to four weeks of storage
of the disc. As proof of the concept, CTCs from a breast-
cancer patient were enumerated and subsequently retraced
and characterized with HER2 antibody. To our knowledge,
this is the first study to analyse breast-cancer patient
specimens using the CytoTrack system. From the patient
cells on the disc, we generated a map of the CTCs which
allows retracing of individual CTCs for subsequent
biomarker analysis.
Treatment of metastatic breast cancer is currently guided
by  characterization  of  cells  of  the  primary  tumour,
although 90% of deaths due to breast cancer occur as a
consequence  of  metastases.  In  up  to  50%  of  all  breast
cancer patients the molecular profile of the metastases is
different  from  the  primary  tumour  that  is  currently
guiding treatment [8,19]. Interest in investigating whether
CTCs can be  used as  a  tool  for  characterization of  the
metastatic events has therefore begun to grow [7]. Whole-
cell  analysis  methods  often  require  selection  or  enrich‐
ment  of  CTCs  by  morphological  properties,  size  or
selection/depletion  by  immunocapture  techniques  [14].
The  CytoTrack  system  immobilizes  all  nucleated  cells
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without  prior  selection,  depletion  or  enrichment  and
furthermore  provides  a  combined  concept  for  both
enumeration and characterization [10].
Beside CytoTrack other methods are looking beyond
enumeration, such as EPIC Science’s CTC platform or the
FDA-approved CellSearch method – the latter in combina‐
tion with for example the DEPArray system – to uncover
mutations of individual CTCs [19]. As the enumeration
procedures are linked to epithelial biomarkers, such as
cytokeratins in CytoTrack and the HD-CTC assay, or
EpCAM in CellSearch, current methods have advantages
and pitfalls [20,21]. During the CTC detection/enumeration
step some cancer cells in a blood sample might not be traced
with the specific biomarkers applied by the assays because
of the possibly heterogenic population of CTCs, where
mutations and epithelial-mesenchymal transition may
have occurred. Only larger clinical studies can reveal
whether present CTC enumeration and characterization
methods can unravel the individual metastatic heteroge‐
neity to a degree that will refine treatment strategies and
achieve better outcomes.
In this study, we confirmed the applicability of the Cyto‐
Disc for retracing of CTCs, and studies are ongoing in our
group to develop downstream analysis of existing cancer
biomarkers, such as HER2 in breast cancer. The HER2
characterization of individual CTCs and retracing in one
patient in this study provides proof-of-concept for such on-
disc downstream analysis. Future studies must investigate
if the CytoTrack method is compatible for further down‐
stream analyses such as, e.g., FISH, and rolling circle
amplifications (RCA) using different types of markers for
proteins, RNA and DNA.
The generated map facilitates individual CTC imaging both
during the initial CTC enumeration and during the
subsequent characterization. The map may also serve as a
template for application of reagents directly onto individ‐
ual CTCs, thus limiting the volume of reagents required for
analysis.
This study shows that storage of the disc is possible and
cells can be retraced after four weeks of storage. However,
we have not shown if storage is compatible with specific
CTC characterization analysis. This certainly also depends
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Figure 4. Same field of view before and after removal of CytoCover and mounting medium. 
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Figure 4. Same field of view before and after removal of CytoCover and mounting medium. After removal, the disc was imaged on the same day and after
three and four weeks to measure potential distance shift in fields of view. Levels of precision are slightly different between image acquisitions. The image
position shift is illustrated by the red circle around a cell.
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on the stability of the chosen biomarker at different
temperatures, and possibly other conditions. Potentially,
individual CTCs may even be analysed multiple times
provided the tested biomarkers are stable. Thus, storage




Figure 5. Images (top) and cell count (bottom) of nucleated cells before and after removal 
of CytoCover and mounting medium. The arrows illustrate examples of differences in cell 
counting caused by shifting of the field of view. Thus, some cells may be visible in one field 
of view but not the other. 
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Figure 6. Images (anti-cytokeratin/Green, nuclear stain DAPI/Blue, anti-HER2/NIR and/or anti-CD45/NIR) of the same fields of view after CTC enumeration
(left) and after HER2 characterization (right) for three fields of view containing four CTCs. HER2 membrane staining of each individual CTC is observed
together with CD45 membrane staining after HER2 characterization.
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The CytoTrack system with the new CytoDisc allows
retracing and potentially extended CTC characterization;
future studies may use this to test specific CTC biomarker
analyses. CTC characterization has the potential to enhance
personalized metastatic cancer therapy.
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